LLY vs AMGN
By Alex · Tickerpine
Eli Lilly and Company vs Amgen Inc., side by side — the numbers that matter, in plain English. No “winner” hype; you decide.
| Metric | LLY | AMGN |
|---|---|---|
| Price | $1,220.28 | $416.18 |
| Market cap | $1.09T | $225.15B |
| P/E ratio | 41.0 | 25.7 |
| ROE | 102.29% | 91.47% |
| Profit margin | 33.53% | 22.95% |
| Revenue growth | 47.70% | 9.50% |
| Dividend yield | 0.57% | 2.43% |
| Beta | 0.51 | 0.41 |
Green = the more favorable figure for that metric (lower P/E, higher ROE, margin, growth and yield). Not a recommendation.
LLY vs AMGN in plain English
- LLY is the bigger company — about 4.8× the market cap of AMGN.
- AMGN is cheaper on earnings (P/E 25.7 vs 41.0).
- LLY earns a higher return on equity (102% vs 91%).
- LLY is growing revenue faster (48% vs 10%).
- AMGN has the higher dividend yield (2.43% vs 0.57%).
How would $1,000 have done in each?
LLY return calculator
See what $1,000 in Eli Lilly and Company would be worth today.
AMGN return calculator
See what $1,000 in Amgen Inc. would be worth today.
Figures from public market data, may be delayed. Comparison is informational only — not investment advice.